{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011025","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.682484+00:00","generated_at":"2026-06-25T05:36:00.761046+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Terns Pharmaceuticals appoints Kerry Russell as Chief Medical Officer effective June 1, 2022","bullets":["Kerry Russell, M.D., Ph.D., named CMO, reporting to President and Head of R&D Erin Quirk, M.D.","Dr. Russell previously VP of late clinical development at Dicerna Pharmaceuticals (acquired by Novo Nordisk).","She held leadership roles at resTORbio, Novartis, and was an NIH-funded associate professor at Yale.","Terns expects key clinical data readouts for TERN-501, TERN-601, and TERN-701 across NASH, obesity, and CML."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011025","json":"https://secwatch.observer/filing/0000950170-22-011025.json","markdown":"https://secwatch.observer/filing/0000950170-22-011025.md","text":"https://secwatch.observer/filing/0000950170-22-011025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/0000950170-22-011025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/tern-20220601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:36:00.761046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}